Learn, Analyse & Invest
only with
only with
+91
Download Orca
Astal Laboratories Ltd.
Astal Laboratories
₹ 0.00
0.00 (0.00)%
NSE
BSE
Healthcare
Small-cap - With a market cap of ₹2.62 Cr.
| EX-Date | Purpose |
|---|---|
| 30 06 2021 | Quarterly Results & Audited Results |
| 12 08 2021 | Quarterly Results |
| 01 09 2021 | A.G.M. |
| 10 11 2021 | Quarterly Results |
| 08 02 2022 | Quarterly Results |
| 30 05 2022 | Quarterly Results |
| 11 08 2022 | Quarterly Results |
| 08 09 2022 | A.G.M. |
| 18 10 2022 | Inter alia, to consider and approve the Directors resignation |
| 14 11 2022 | Quarterly Results |
| 23 12 2022 | Inter alia, to transact the following business: 1. To Approve the Notice for calling an Extra-Ordinary General Meeting (EGM) along with fixing of date of Book closure and e-voting period 2. To appoint Scrutinizer to scrutinize voting during the EGM and remote e-voting. 3. To appoint Mr. Kommera Harish as the Chief Executive Officer (CEO) of the Company on such terms and conditions decided by the board. 4. To appoint Mr. Nikhil CS as the Chief Operating Officer (COO) of the Company on such terms and conditions decided by the board. 5. To authorize Mr. Sudheer Karna Kankanala, whole time director for filing e-forms and other statutory compliances connected to the business, and the proposed Extra Ordinary General Meeting. 6. To adopt a new set of Memorandum of Association (MOA) of the Company as per the Companies Act, 2013. 7. To adopt a new sets of Articles of Association (AOA) of the Company containing regulations in conformity with the Companies Act, 2013. 8. To re-constitute Audit Committee of the Company. 9. To re-constitute Nomination & Remuneration Committee of the Company 10. To re-constitute Stakeholders Relationship Committee of the Company 11. To Open Banking Accounts with Canara Bank, RBL Bank, ICICI Bank and State Bank of India on behalf of the company at Hyderabad and Authorize Kommera Harish CEO and/or Nikhil CS, COO to file the required documentation and act as authorized signatories on behalf of the company. 12. To take all statutory approvals and Licenses from necessary regulators including GST, Drug Licenses, Import, Export Code (IEC) and also other licenses and transact any other business with the permission of the Chair. 13. To open a corporate office at Hyderabad, Telangana State, India. 14. Any other matter with the permission of chair. |
| 14 02 2023 | Quarterly Results |
| 27 05 2023 | Audited Results |
| 15 07 2023 | Quarterly Results |
| 16 08 2023 | Macro International Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 16/08/2023 ,inter alia, to consider and approve In terms of Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, this is to inform you that the meeting of the Board of Directors of the Company will be held on Wednesday, 16th August, 2023 at corporate office of the Company at 304, 3rd Floor Babukhan Estate, Basheerbagh, Hyderabad Telangana 500001 to transact the following business: 1. To consider & approve Board Report along with all other necessary Annexure for the financial year ended March 31, 2023. 2. To discuss/ finalize the proposal for Issue of Equity Shares of the Company on Preferential Basis to raising of additional capital by the Company pursuant to Section 42, 62 of the Companies Act, 2013 and as per the SEBI (Issue of Capital and Disclosure Requirement) Regulation, 2018. 3. To consider increase in Authorized Share Capital of the Company and consequent alteration in Capital Clause of the Memorandum of Association of the Company. |
| 18 08 2023 | Preferential Issue of shares (Revised) & Increase in Authorised Capital & A.G.M. |
| 13 10 2023 | Inter alia, to transact the following business: 1. To allotment of 980000 equity shares on Preferential Basis. 2. Any other matter with the permission of chair |
| 10 11 2023 | Quarterly Results |
| 20 12 2023 | Preferential Issue of shares & Increase in Authorised Capital |
| 09 02 2024 | Quarterly Results |
| 12 11 2024 | Quarterly Results |
| 27 11 2024 | Inter alia, to consider and approve the following: 1. To Allot 40,79,930 Convertible Warrants convertible into equity shares of face value of Rs. 10/- each at premium of Rs. 30/- each to Strategic Investors (Non-Promoters) on Preferential basis. 2. Any other matter with the permission of chair |
| 27 01 2025 | Quarterly Results |
| 19 05 2025 | Audited Results |
| 12 08 2025 | A.G.M. & Quarterly Results |
| 09 10 2025 | Preferential Issue of shares & Increase in Authorised Capital & Inter alia, to consider and approve:- 1) To increase authorised share capital of the Company in accordance with Companies Act, 2013 and subject to any regulatory/ statutory approvals, as may be required and the approval of the shareholders of the Company; 2) To consider and if thought fit, approve the issuance of equity shares / convertible warrants of the Company on a preferential basis in accordance with the Companies Act, 2013 read with the rules notified thereunder, each as amended, and the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended and such other acts, rules and regulations, as may be applicable, subject to any regulatory/ statutory approvals, as may be required and the approval of the shareholders of the Company; and other items. |
| 14 11 2025 | Quarterly Results |
| 14 02 2026 | Quarterly Results |
News
